Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ACANYA is a topical gel combination of clindamycin phosphate (an antibacterial lincosamide) and benzoyl peroxide (an oxidizing bactericidal agent) approved in 2008 for acne vulgaris. The dual mechanism targets bacterial growth and inflammation while promoting keratolytic effects. It is indicated as a monotherapy or adjunctive treatment for moderate acne in adolescents and adults.
ACANYA is in peak lifecycle stage with modest Part D utilization (26 claims, $14K annually in 2023), indicating mature, stable market position with limited growth headroom.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
Worked on ACANYA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~4 years — strategic planning for patent cliff underway
ACANYA is a mature, peak-stage topical dermatology brand with minimal growth prospects and zero active job openings listed. Working on this product offers stable, established market management experience but limited career trajectory or product expansion opportunities.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo